Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.81 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | TSPO | P30536 | 1/20 | 0.66 |
| ▸ | BRD2 | P25440 | 6/20 | 0.65 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.63 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.63 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | BRD1 | O95696 | 1/20 | 0.63 |
| ▸ | CCL2 | P13500 | 1/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | EP300 | Q09472 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544021 | 0.90 | BRD4 (0.82) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL17884718 | 0.90 | BRD4 (0.82) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL18894409 | 0.90 | BRD4 (0.82) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL15980842 | 0.90 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL19556888 | 0.90 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL18017604 | 0.90 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL23744911 | 0.88 | BRD4 (0.68) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL19764194 | 0.87 | BRD4 (0.81) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL24391068 | 0.85 | BRD4 (0.83) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL21501429 | 0.85 | BRD4 (0.82) | BRD4DNERADORA3TSPOBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180009779-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009779-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885DNER 1938/4885ADORA3 4664/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | BRD4 1674/4885DNER 184/4885ADORA3 3982/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885DNER 1938/4885ADORA3 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.